Loading: 100%
Profit & Loss StatementP&L data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reasons:
- It is not known how cost items are reported in the original P&L
- Not all line items from the original statement have been associated with a standardised figure (16 items missing)
No data available for the selected time periods
in million USD FY '10FY '11FY '12FY '13FY '14FY '15FY '16
Contract manufacturing revenue
13
9
15
21
22
27
44
Government contract revenue
14
5
0
0
0
0
0
License revenue
0
0
0
0
0
0
0
Total revenues
28
13
15
22
22
27
45
Cost of contract manufacturing
9
7
10
13
13
16
23
Research and development
25
29
36
24
28
43
60
Selling, general and administrative
8
11
11
13
17
19
19
Total costs and expenses
42
48
57
50
58
77
101
Loss from operations
-14
-35
-42
-28
-36
-50
-56
Interest and other income
0
1
0
0
0
0
1
Loss on early extinguishment of debt
0
0
0
-2
0
0
0
Interest and other expense
-1
-1
0
0
0
0
0
Net loss
-14
-34
-42
-30
-35
-50
-56
Series E preferred stock accumulated dividends
0
0
0
0
0
-4
-4
Net loss attributable to common stockholders
0
0
-42
-30
-36
-54
-60
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Jul 14, 2014 n/a
calculated values,
restated on Jul 14, 2015 n/a
calculated values,
restated on Jul 14, 2016 n/a
calculated values,
restated on Jul 14, 2016 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
Balance SheetBS data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (34 items missing)
No data available for the selected time periods
in million USD FY '10FY '11FY '12FY '13FY '14FY '15FY '16
Assets
Cash and cash equivalents
n/a
23
18
35
77
68
61
Trade and other receivables, net
n/a
1
2
2
1
4
3
Government contract receivables
n/a
0
0
0
0
0
0
Inventories, net
n/a
5
4
4
6
7
16
Prepaid expenses and other current assets, net
n/a
1
1
1
1
1
1
Total current assets
n/a
31
25
42
86
81
82
Leasehold improvements
n/a
1
1
1
2
2
0
Laboratory equipment
n/a
4
5
5
6
6
0
Furniture, fixtures, office equipment and software
n/a
2
2
3
3
4
0
Construction-in-progress
n/a
0
0
0
0
12
0
Property and equipment, gross
n/a
7
9
9
10
23
0
Less accumulated depreciation and amortization
n/a
-5
-6
-7
-7
-8
0
Property and equipment, net
n/a
2
3
3
2
15
24
Restricted cash
n/a
0
0
0
0
0
1
Other assets
n/a
2
1
0
2
2
2
Total assets
n/a
35
28
45
91
97
109
Liabilities and owners' equity
Accounts payable
n/a
4 4046000
3 3492000
3 2821000
2 2434000
10 10385000
8 8429000
Accrued clinical trial and related fees
n/a
2 2292000
2 2111000
1 930000
4 4433000
4 3910000
8 7594000
Accrued payroll and related costs
n/a
1 1455000
2 2468000
4 3582000
4 3837000
5 4606000
6 5821000
Notes payable, current portion and net of discount
n/a
1 1321000
0 0
0 0
0 0
0 0
0 0
Deferred revenue, current portion
n/a
6 5617000
4 3651000
4 4171000
5 5241000
7 6630000
10 10030000
Customer deposits
n/a
2 1759000
5 4865000
8 8059000
6 5760000
11 11363000
24 24212000
Other current liabilities
n/a
1 1189000
1 1052000
1 998000
1 502000
0 437000
1 1488000
Total current liabilities
n/a
18 17679000
18 17639000
21 20561000
22 22207000
37 37331000
58 57574000
Deferred revenue, less current portion
n/a
1 632000
0 361000
0 292000
0 292000
0 0
0 0
Other long-term liabilities
n/a
1 1037000
1 779000
0 445000
0 0
0 0
0 0
Deferred rent, less current portion
n/a
0 0
0 0
0 0
0 347000
1 1098000
1 1395000
Commitments and contingencies
n/a
0 0
0 0
0 0
0 0
0 0
0 0
Preferred stock
n/a
0 0
0 0
0 0
0 1000
0 2000
0 2000
Common stock
n/a
0 70000
0 101000
0 143000
0 179000
0 193000
0 237000
Additional paid-in-capital
n/a
311 311353000
348 347506000
392 391521000
471 470785000
512 512464000
559 559111000
Accumulated deficit
n/a
-296 -296005000
-338 -338124000
-368 -367904000
-403 -403266000
-454 -453624000
-509 -509276000
Total stockholders' equity
n/a
15 15418000
9 9483000
24 23760000
68 67699000
59 59035000
50 50074000
Total liabilities and stockholders' equity
n/a
35 34766000
28 28262000
45 45058000
91 90545000
97 97464000
109 109043000
Remarks restated on n/a restated on Nov 30, -1 n/a restated on Nov 30, -1 n/a restated on Nov 30, -1 n/a restated on Jul 14, 2015 n/a restated on Nov 30, -1 n/a restated on Dec 12, 2016 n/a
Cash Flow StatementCF data quality: 0% (?)
edit
No data available yet
Loading data...
No data available for the original financial statements for the selected time periods. You can change the selected time periods by clicking on 'data' on the top right.
Standardised statements can't be displayed.
Reason:
- Not all line items from the original statement have been associated with a standardised figure (39 items missing)
No data available for the selected time periods
in million USD FY '10FY '11FY '12FY '13FY '14FY '15FY '16
Net loss
-14
-34
-42
-30
-35
-50
-56
Share-based compensation
1
3
3
3
6
7
5
Depreciation and amortization
0
1
1
1
1
1
2
Loss on early extinguishment of debt
0
0
0
2
0
0
0
Amortization of discount on notes payable and debt issuance costs
0
0
0
0
0
0
0
Amortization of expenses paid in shares of common stock
0
1
0
0
0
0
0
Common stock issued for services
0
0
0
0
0
0
0
Loss on disposal of property and equipment
0
0
0
0
0
0
0
Trade and other receivables, net
0
0
-1
1
0
-2
1
Government contract receivables
2
0
0
0
0
0
0
Inventories
2
-2
2
-1
-1
-2
-9
Prepaid expenses and other current assets, net
-1
0
0
0
-1
0
0
Restricted cash
0
0
0
0
0
0
-1
Other non-current assets
0
0
1
0
0
0
0
Accounts payable
0
1
-1
-1
0
3
-4
Accrued clinical trial and related fees
1
1
0
-1
4
-1
4
Accrued payroll and related costs
0
0
1
1
0
1
1
Deferred revenue
-1
4
-2
0
1
1
3
Deferred government contract revenue
-4
0
0
0
0
0
0
Customer deposits
0
-1
3
3
-2
6
13
Other accrued expenses and current liabilities
0
0
0
0
0
0
1
Other long-term liabilities
0
0
0
0
0
0
0
Proceeds from sale of property
0
0
0
0
0
0
0
Deferred rent, less current portion
0
0
0
0
0
1
0
Net cash used in operating activities
-14
-26
-36
-21
-28
-36
-40
Property and equipment acquisitions
0
-1
-2
-1
-1
-9
-9
Decrease (increase) in other assets
0
0
0
0
-2
1
1
Net cash used in investing activities
0
-1
-1
-1
-3
-8
-9
Proceeds from issuance of common stock, net of issuance costs of $1,007,000 and $630,000, respectively
25
33
33
40
54
19
45
Proceeds from issuance of Series E preferred stock, net of issuance costs of $1,000, $1,002,000 and $1,458,000, respectively
0
0
0
0
18
18
0
Proceeds from issuance of notes payable, net of issuance costs of $251,000
0
0
0
15
0
0
0
Proceeds from issuance of common stock under the Employee Stock Purchase Plan
0
0
0
1
1
1
1
Proceeds from exercise of stock options
0
0
0
0
1
0
0
Dividends paid on preferred stock
0
0
0
0
0
-3
-4
Principal payments on notes payable
-2
-2
-1
-15
0
0
0
Payment of final fee on notes payable
0
0
0
-1
0
0
0
Principal payments on capital leases
0
0
0
0
0
0
0
Net cash provided by financing activities
24
31
32
39
73
35
42
Net (decrease) increase in cash and cash equivalents
10
3
-5
17
42
-9
-7
Remarks
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Jul 14, 2014 n/a
calculated values,
restated on Jul 14, 2015 n/a
calculated values,
restated on Jul 14, 2016 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,
restated on Nov 30, -1 n/a
calculated values,